Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

NCT03449901 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT03449901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03449901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Completed
Start date
May 9, 2018
Completion date
July 8, 2022
Enrollment
98 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma